EMV Capital PLC · LSE:EMVC

EMV Capital — ProAxsis — 2nd Annual Capital Markets Day (March 2017)

23 slides from EMV Capital's conference presentation, March 2017

  1. Slide 1: New standard of care for respiratory disease

    Slide 1: New standard of care for respiratory disease

    2nd Annual Capital Markets Day Professor Brian Walker Co-Founder & CSO, ProAxsis Ltd New standard of care for respiratory disease

  2. Slide 2: Prof. Brian Walker

    Slide 2: Prof. Brian Walker

    Detect, capture and measure proteases Prof. Brian Walker Chief Scientific Officer Brian.Walker@proaxsis.com www.proaxsis.com @ProAxsis

  3. Slide 3: Proteases are involved in multiple diseases

    Slide 3: Proteases are involved in multiple diseases

    Proteases are involved in multiple diseases AIDS SalesDiabetes (HIV Protease) (DPP IV) Alzheimer’s (β and γ-secretase) Angiodema (Kallikrein) Pulmonary embolism Hypertension (Thrombin, Factor Xa) (ACE/NEP/ECE) Arthritis/Inflammation Heart attack (TACE, MMPs) (Thrombin, Factor Xa) Chronic wounds Prot

  4. Slide 4: ProteaseTags offer a novel solution

    Slide 4: ProteaseTags offer a novel solution

    ProteaseTags® offer a novel solution  Small chemical probes that act as irreversible inhibitors targeting the active site of specific proteases  Allows the capture of active proteases in multiple biological samples 3

  5. Slide 5: Incorporating ProteaseTags in to an Activity Based Immunoassay

    Slide 5: Incorporating ProteaseTags in to an Activity Based Immunoassay

    Incorporating ProteaseTags® in to an Activity Based Immunoassay Sample containing Biotin- Multiple proteases ProteaseTag Target protease captured Streptavidin Coated well ProteaseTag binds to streptavidin Antibody-HRP HRP Substrate Antibody binds to captured protease

  6. Slide 6: New standard of care for respiratory disease

    Slide 6: New standard of care for respiratory disease

    2nd Annual Capital Markets Day Dr David Ribeiro CEO, ProAxsis Ltd New standard of care for respiratory disease

  7. Slide 7: Dr. David Ribeiro, PhD

    Slide 7: Dr. David Ribeiro, PhD

    Detect, capture and measure proteases Dr. David Ribeiro, PhD Chief Executive Officer David.Ribeiro@proaxsis.com www.proaxsis.com @ProAxsis

  8. Slide 8: An experienced leadership team

    Slide 8: An experienced leadership team

    An experienced leadership team Dr. David Ribeiro – CEO Senior management at Pfizer, Solvay Healthcare and Encysive Pharma. Most recently, at Pharmaxis, worked on a diagnostic test for assessing bronchial hyper-responsiveness in asthma, and a therapeutic product designed for the chronic treatment of

  9. Slide 9: Our Vision for ProAxsis

    Slide 9: Our Vision for ProAxsis

    Our Vision for ProAxsis  To become the premier company for the provision of robust, sensitive and highly specific assays for the measurement of active proteases.  To translate this technology platform to Point-of-Care devices for protease biomarker diagnostics. 3

  10. Slide 10: Proteases are involved in multiple diseases

    Slide 10: Proteases are involved in multiple diseases

    Proteases are involved in multiple diseases AIDS SalesDiabetes (HIV Protease) (DPP IV) Alzheimer’s (β and γ-secretase) Angiodema (Kallikrein) Pulmonary embolism Hypertension (Thrombin, Factor Xa) (ACE/NEP/ECE) Arthritis/Inflammation Heart attack (TACE, MMPs) (Thrombin, Factor Xa) Chronic wounds Prot

  11. Slide 11: COPD is an umbrella term used to describe progressive lung diseases

    Slide 11: COPD is an umbrella term used to describe progressive lung diseases

    COPD is an umbrella term used to describe progressive lung diseases 16.3m diagnosed in EU, 17.7m US, >75m China UK hospital admission for exacerbation £5000. 9 days in hospital with IV antibiotics. 5

  12. Slide 12: 40,000 EU and 30,000 US Diagnosed

    Slide 12: 40,000 EU and 30,000 US Diagnosed

    CF is a life-limiting inherited condition caused by a faulty gene 40,000 EU and 30,000 US Causes mucus to gather in the lungs Diagnosed and digestive system and creates a range of challenging symptoms 6

  13. Slide 13: A world-renowned scientific advisory board

    Slide 13: A world-renowned scientific advisory board

    A world-renowned scientific advisory board Prof Stuart Elborn (Belfast) – Chairman Dean of the School of Medicine, Dentistry and BioMedical Sciences Former President of European CF Society Prof Marcus Mall (Heidelberg) Prof Patrick Flume (South Carolina) Director of the Dept. of Translational Profes

  14. Slide 14: No suitable biomarker test….until now

    Slide 14: No suitable biomarker test….until now

    No suitable biomarker No suitable test….until biomarker now test available until now  C-reactive protein (CRP) levels are sometimes measured in the clinic, but KOLs noted that this is not a reliable predictor of exacerbations as CRP levels are often normal even when the patient is having an exacerb

  15. Slide 15: Elevated NE is predictive of exacerbation

    Slide 15: Elevated NE is predictive of exacerbation

    Elevated NE is predictive of exacerbation 400 NE Activity (ng/ml) 300 200 100 0 Stable Exacerbation Sputum NE is the most informative biomarker to monitor disease activity Elevations in sputum NE levels predict time to next exacerbation and future hospital admissions* Moffitt et al, P102, British Th

  16. Slide 16: First Activity based immunoassay kit for measuring NE now launched

    Slide 16: First Activity based immunoassay kit for measuring NE now launched

    First Activity based immunoassay kit for measuring NE now launched  Recent kit supplies to UK, Ireland, Germany, Switzerland, Sweden and USA  CE Mark expected in H2 2016  Immunoassay accepted for use in a pharma company trial, and being validated by several others  Research collaborations with a

  17. Slide 17: First Point of Care test due to launch in 2017

    Slide 17: First Point of Care test due to launch in 2017

    First Point of Care test due to launch in 2017 Launch strategy  CE mark  Launch first as general IVD for use in clinic – elevate clinician awareness  Follow-up launch as point-of-care IVD for use by the patient at home Business model  Western/Northern Europe: Direct sales  Rest of Europe/Asia/U

  18. Slide 18: Minimal current competition

    Slide 18: Minimal current competition

    Minimal current competition Aseptika NEATstik™ Exotoxin A Active NE as marker of lung disease Test + Iron transport molecule as marker of P. activity aeruginosa infection Sample Sputum Sputum Lab-based version?   Detects all exacerbations?  X limited to those due to PA infection Platform of respi

  19. Slide 19: Timeline for POC market entry

    Slide 19: Timeline for POC market entry

    Timeline for POC market entry 2015 2016 2017 H2 H1 H2 H1 Immunoassay launch POC development Validation Transfer to manufacturing Series A close CE marking – general IVD CE marking – self test EU launch – general IVD EU launch – self test 13

  20. Slide 20: Key drivers of the POC market

    Slide 20: Key drivers of the POC market

    Key drivers of the POC market  Target population is moderate-severe COPD and adult CF patients (48 million)  Greater than 85% of KOLs expected moderate-to-high usage of NEATstik POC amongst their colleagues working with CF and COPD patients  Launch of NEATstik planned for H1 2017 in Europe and H1

  21. Slide 21: Fundraising up to £7million

    Slide 21: Fundraising up to £7million

    Use of proceeds to drive success Fundraising up to £7million  Prospective pan-European COPD trial  Complete NEATstik POC development programme and CE marking  Build commercial team and launch across Europe  Ongoing development and launch of further respiratory protease target assays 15

  22. Slide 22: Protease diagnostics company

    Slide 22: Protease diagnostics company

    Protease diagnostics company  Developing and commercializing immunoassay kits and rapid, highly sensitive point-of- care (POC) tests for the capture, detection and measurement of active protease biomarkers of disease  Launched first immunoassay kit to pharma drug development and academic research

  23. Slide 23: Any Questions?

    Slide 23: Any Questions?

    Any Questions? David.Ribeiro@proaxsis.com www.proaxsis.com @proaxsis

Source: Internet Archive copy of netscientific.net

More decks from EMV Capital PLC

All 17 EMV Capital decks